FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.
What happened
FDA reviewed Natuzem's website, https://natuzem.com/, in September 2026 and found the products marketed with claims to treat diseases. Because those claims make the products drugs, and FDA has no approved applications for them, FDA calls them unapproved new drugs. FDA also said earlier lab tests of products with similar names found undeclared drug ingredients, though FDA has not sampled these specific products from Natuzem's inventory.
What FDA found
The website claims these products treat or prevent diseases, such as reducing premature ejaculation, treating arthritis, or protecting against bone cancer, which makes them drugs under the law.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128The products are not generally recognized as safe and effective, and FDA has no approved application for any of them, so they are unapproved new drugs.
Section 201(p) and 505(a) of the FD&C Act, 21 U.S.C. 321(p) and 355(a)Shipping these unapproved drugs across state lines violates the law.
Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)FDA says it is the firm's legal duty to make sure products it sells contain no undeclared or harmful ingredients, after earlier tests of similarly named products found hidden drug ingredients.
What FDA wants
Send a written response to FDAAdvisory@fda.hhs.gov within 15 business days of receiving the letter, listing the specific steps taken to fix the violations and to prevent them from happening again, with supporting documents, and put reference number 737558 in the subject line.
Who should pay attention
- online sellers of herbal or joint-health products shipping to the United States
- consumers buying arthritis or sexual-health products from foreign websites
- distributors and marketplaces that list products such as Reumofan Plus or Artrifan King
This is a summary. Read the original letter on fda.gov.